PFE Jan 2023 80.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:55PM EDT. Market open.
| Previous close | 30.56 |
| Open | 30.60 |
| Bid | 30.05 |
| Ask | 30.70 |
| Strike | 80.00 |
| Expiry date | 2023-01-20 |
| Day's range | 30.52 - 30.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 94 |
- Zacks
FDA Panel Recommends Modifying COVID Jabs to Target Omicron
The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.
- GlobeNewswire
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful resultsPriovant is developing brepocitinib in severe autoimmune diseases with few approved therapies and where dual inhibition of TYK2 and JAK1 may provide greater efficacy than inhibiting either aloneA single registrational Phase 3 trial evaluating oral brepocitinib in derm
© 2022 Yahoo. All rights reserved.
